Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

COMPUGEN LTD.

(CGEN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies
Communiqués de presse de la société COMPUGEN LTD.
11/12COMPUGEN : Q3 Earnings Snapshot
AQ
11/12Press Release dated November 12, 2021 – “Compugen Presents Preliminary Resu..
PU
11/12Compugen Announces Collaboration Expansion with Bristol Myers Squibb alongside $20 Mill..
PU
11/12Compugen Presents Preliminary Results from Phase 1 Dose Escalation Monotherapy Study of..
PR
11/12Compugen Presents Initial Translational Data Supporting the Differentiation of PVRIG Co..
PR
11/12Compugen Presents Preliminary Results from Phase 1/2 Dose Escalation Study of COM701 wi..
PR
11/12Compugen Reports Third Quarter 2021 Results
PR
11/11Compugen Announces Collaboration Expansion with Bristol Myers Squibb alongside $20 Mill..
PR
11/08Compugen to Present at Upcoming Investor Conferences
PR
10/26Compugen to Release Third Quarter 2021 Results on Friday, November 12, 2021
PR
10/04COMPUGEN : Announces Milestone Payment from AstraZeneca Triggered by First Patient Dosed w..
PR
10/01COMPUGEN : To Present Clinical Data from anti-TIGIT COM902 Monotherapy and Triple Combinat..
PR
09/22COMPUGEN : Awarded Top 50 Most Promising Microsoft Solution Providers by CIOReview
AQ
09/14COMPUGEN : to Present at the Cantor Global Healthcare Conference
PU
08/26COMPUGEN : to Present at the Morgan Stanley 19th Annual Global Healthcare Conference
PR
08/19COMPUGEN : Announces Bispecific Antibody Derived from COM902 to Enter Clinical Development
PR
07/28COMPUGEN : Q2 Earnings Snapshot
AQ
07/28COMPUGEN : Reports Second Quarter 2021 Results (Form 6-K)
PU
07/28COMPUGEN : Reports Second Quarter 2021 Results
PR
07/19COMPUGEN : Doses First Patient in Phase 1/2 Triple Combination Cohort Expansion of COM701 ..
PR
07/15COMPUGEN : Doses First Patient in Phase 1 Combination Study of COM902 and COM701 in Patien..
PR
07/14COMPUGEN : to Release Second Quarter 2021 Results on Wednesday, July 28, 2021
PR
06/30COMPUGEN : Doses First Patient in COM701/Opdivo® (nivolumab) Phase 1b Cohort Expansion Stu..
PR
06/29COMPUGEN : Presents Research Supporting PVRIG as a Novel and Differentiated Checkpoint in ..
PR
06/08COMPUGEN : Preliminary biomarker data reveal immune activation evidenced by a trend of inc..
PU
06/08COMPUGEN : Announces Updated Data from Phase 1 Study of COM701, First- in-Class Anti-PVRIG..
PR
05/13COMPUGEN : Q1 Earnings Snapshot
AQ
05/11COMPUGEN TO PARTICIPATE AT SITC'S TA : A Deep Dive Seminar Series
PR
05/10COMPUGEN : Announces Expansion of Research Collaboration with Johns Hopkins University for..
PR
05/03COMPUGEN : to Release First Quarter 2021 Results on Thursday, May 13, 2021
PR
04/27COMPUGEN : Publishes Preclinical Data Demonstrating Therapeutic Potential of COM902 in Can..
PR
03/08COMPUGEN : to Present at the Oppenheimer 31st Annual Healthcare Conference
PR
02/25COMPUGEN : Annual Report (SEC Filing - 20-F)
PU
02/25COMPUGEN : 4Q Earnings Snapshot
AQ
02/25COMPUGEN : Reports Fourth Quarter and Full Year 2020 Results
PR
02/23BRISTOL MYERS SQUIBB : Compugen Expands Clinical Collaboration Agreement with Bristol Myer..
AQ
02/22COMPUGEN : Expands Clinical Collaboration Agreement with Bristol Myers Squibb with Phase 1..
PR
02/16COMPUGEN : to Release Fourth Quarter and Full Year 2020 Results on Thursday, February 25, ..
PR
2020COMPUGEN : Announces First Development Milestone in License Agreement with AstraZeneca for..
PR
2020COMPUGEN : to Present at Upcoming Investor Conferences
PU
2020COMPUGEN : to Present at Upcoming Investor Conferences
PR
2020COMPUGEN : 2020 Third Quarter Financial Results
PU
2020COMPUGEN : 3Q Earnings Snapshot
AQ
2020COMPUGEN : Reports Third Quarter 2020 Results
PU
2020COMPUGEN : Reports Third Quarter 2020 Results
PR
2020COMPUGEN : Further Expands Patent Portfolio for TIGIT Inhibitor COM902 with Composition of..
PU
2020COMPUGEN : Further Expands Patent Portfolio for TIGIT Inhibitor COM902 with Composition of..
PR
2020COMPUGEN : Presents New Research Data Further Supporting PVRIG as a Potentially Promising ..
PU
2020COMPUGEN : to Release Third Quarter 2020 Results on Thursday, November 5, 2020
PU
2020COMPUGEN : to Release Third Quarter 2020 Results on Thursday, November 5, 2020
PR
2020COMPUGEN : Announces Addition of Immuno-oncology Pioneer Dr. Nils Lonberg to its Scientifi..
PU
2020COMPUGEN : Doses First Patient in Phase 1/2 Triple Combination Study of COM701 with Bristo..
PU
2020BRISTOL MYERS SQUIBB : Compugen Doses First Patient in Phase 1/2 Triple Combination Study ..
AQ
2020COMPUGEN : Doses First Patient in Phase 1/2 Triple Combination Study of COM701 with Bristo..
PR
2020COMPUGEN : to Present at Upcoming September 2020 Investor Conferences
PR
2020COMPUGEN : Expands Patent Portfolio for TIGIT Inhibitor COM902 with New US Composition of ..
PR
2020BRISTOL MYERS SQUIBB : Compugen Reports Second Quarter 2020 Results
AQ
2020COMPUGEN : 2Q Earnings Snapshot
AQ
2020COMPUGEN : to Release Second Quarter 2020 Results on Thursday, July 30, 2020
PR
2020BRISTOL MYERS SQUIBB : Compugen Announces FDA Clearance of IND Application for Phase 1/2 T..
AQ
2020COMPUGEN : Announces FDA Clearance of IND Application for Phase 1/2 Triple Combination Stu..
PR
2020COMPUGEN : Doses First Patient in COM701 Phase 1 Monotherapy Expansion Cohort
PR
2020COMPUGEN : 1Q Earnings Snapshot
AQ
2020COMPUGEN : becomes a partner in the Canadian Coalition for Learning @ Home
AQ
2020COMPUGEN : to Release First Quarter 2020 Results on Wednesday, May 6, 2020
PR
2020COMPUGEN : Expands Intellectual Property Portfolio for COM701 With New European Compositio..
PR
2020COMPUGEN : Announces Publication of BAY 1905254 Preclinical Data in Cancer Immunology Rese..
AQ
2020COMPUGEN : to Present Data Update on COM701 Phase 1 Clinical Trial at the 2020 AACR Virtua..
AQ
2020COMPUGEN : Announces First Patient Dosed in COM902 Phase 1 Trial for Patients With Advance..
PR
2020COMPUGEN : Announces Closing of $75 Million Public Offering of Ordinary Shares
PR
2020COMPUGEN : Announces Pricing of $75 Million Public Offering of Ordinary Shares
PR
2020COMPUGEN : SEC Filing (424B5) - Supplemental Prospectus
PU
2020COMPUGEN : Announces Commencement of Public Offering of Ordinary Shares
PR
2020COMPUGEN : Announces Updated Clinical Data from Ongoing COM701 Phase 1 Study
PR
2020COMPUGEN : 4Q Earnings Snapshot
AQ
1  2  3Next
Upcoming event on COMPUGEN LTD.